Cellosaurus logo
expasy logo

Cellosaurus RMG-II (CVCL_2803)

[Text version]
Cell line name RMG-II
Synonyms RMG2; RMG-2
Accession CVCL_2803
Resource Identification Initiative To cite this cell line use: RMG-II (RRID:CVCL_2803)
Comments Population: Japanese.
Doubling time: ~58 hours (PubMed=1715339); 84 hours (Note=Lot 07132004), ~51 hours (Note=Lot 02032016) (JCRB=JCRB0172.1).
Derived from site: Metastatic; Ascites; UBERON=UBERON_0007795.
HLA typing Source: PubMed=25960936
Class I
HLA-AA*02:07,02:07
HLA-BB*35:01,35:01
HLA-CC*03:03,03:03
Class II
HLA-DQDQB1*02:02,02:02
Disease Ovarian clear cell adenocarcinoma (NCIt: C40078)
Clear cell adenocarcinoma of the ovary (ORDO: Orphanet_398971)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Sex of cell Female
Age at sampling 53Y
Category Cancer cell line
STR profile Source(s): JCRB

Markers:
AmelogeninX
CSF1PO10
D5S81811
D7S82010,12
D13S31714
D16S53910,12
TH017
TPOX8
vWA15,17

Run an STR similarity search on this cell line
Publications

PubMed=1715339; DOI=10.1111/j.1349-7006.1991.tb02713.x
Nozawa S., Yajima M., Sasaki H., Tsukazaki K., Aoki D., Sakayori M., Udagawa Y., Kobayashi T., Sato I., Furusako S., Mochizuki H.
A new CA125-like antigen (CA602) recognized by two monoclonal antibodies against a newly established ovarian clear cell carcinoma cell line (RMG-II).
Jpn. J. Cancer Res. 82:854-861(1991)

PubMed=11330945; DOI=10.1006/gyno.2001.6132
Watanabe T., Imoto I., Kosugi Y., Ishiwata I., Inoue S., Takayama M., Sato A., Inazawa J.
A novel amplification at 17q21-23 in ovarian cancer cell lines detected by comparative genomic hybridization.
Gynecol. Oncol. 81:172-177(2001)

PubMed=12417041; DOI=10.1111/j.1349-7006.2002.tb01213.x
Watanabe T., Imoto I., Katahira T., Hirasawa A., Ishiwata I., Emi M., Takayama M., Sato A., Inazawa J.
Differentially regulated genes as putative targets of amplifications at 20q in ovarian cancers.
Jpn. J. Cancer Res. 93:1114-1122(2002)

PubMed=17671176; DOI=10.1158/0008-5472.CAN-06-4567
Kikuchi R., Tsuda H., Kanai Y., Kasamatsu T., Sengoku K., Hirohashi S., Inazawa J., Imoto I.
Promoter hypermethylation contributes to frequent inactivation of a putative conditional tumor suppressor gene connective tissue growth factor in ovarian cancer.
Cancer Res. 67:7095-7105(2007)

PubMed=24023729; DOI=10.1371/journal.pone.0072162
Anglesio M.S., Wiegand K.C., Melnyk N., Chow C., Salamanca C.M., Prentice L.M., Senz J., Yang W., Spillman M.A., Cochrane D.R., Shumansky K., Shah S.P., Kalloger S.E., Huntsman D.G.
Type-specific cell line models for type-specific ovarian cancer research.
PLoS ONE 8:E72162-E72162(2013)

PubMed=25960936; DOI=10.4161/21624011.2014.954893
Boegel S., Lower M., Bukur T., Sahin U., Castle J.C.
A catalog of HLA type, HLA expression, and neo-epitope candidates in human cancer cell lines.
OncoImmunology 3:e954893.1-e954893.12(2014)

PubMed=25846456; DOI=10.3892/ijo.2015.2951
Takenaka M., Saito M., Iwakawa R., Yanaihara N., Saito M., Kato M., Ichikawa H., Shibata T., Yokota J., Okamoto A., Kohno T.
Profiling of actionable gene alterations in ovarian cancer by targeted deep sequencing.
Int. J. Oncol. 46:2389-2398(2015)

Cross-references
Cell line collections (Providers) JCRB; IFO50316 - Discontinued
JCRB; JCRB0172.1
JCRB; FDSC0028 - Discontinued
Cell line databases/resources cancercelllines; CVCL_2803
CGH-DB; 335-2
CGH-DB; 9363-4
Anatomy/cell type resources BTO; BTO:0004929
Biological sample resources BioSample; SAMN03470819
Encyclopedic resources Wikidata; Q54950667
Gene expression databases GEO; GSM1176284
Polymorphism and mutation databases Cosmic; 1152557
Cosmic; 2582801
Progenetix; CVCL_2803
Entry history
Entry creation04-Apr-2012
Last entry update05-Oct-2023
Version number22